Kailera Therapeutics is trading at $11.79, down -10.21%, amid broader biotech weakness and pressure on growth-oriented valuations. - No company-specific announcement dated September 24, 2026, was identified; Kailera’s latest listed release was its September 16 investor-conference notice. - XBI is down 2.04%, while the S&P 500 and Nasdaq Composite are also lower. - Rising Treasury yields, persistent inflation concerns and higher oil prices are pressuring growth-oriented biotechnology valuations.